The Role of Vascular Endothelial Growth Factor in Metastatic Prostate Cancer to the Skeleton

Emma Roberts, Davina A. F. Cossigny, and Gerald M. Y. Quan

1 Spinal Biology Research Laboratory, University of Melbourne, Department of Surgery, Austin Health, P.O. Box 5555, Heidelberg, VIC 3084, Australia
2 Department of Spinal Surgery, Austin Health, P.O. Box 5555, Heidelberg, VIC 3084, Australia

Correspondence should be addressed to Gerald M. Y. Quan; gerald.quan@austin.org.au

Received 30 June 2013; Revised 4 November 2013; Accepted 14 November 2013

Academic Editor: Manfred Wirth

Copyright © 2013 Emma Roberts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Despite the clinical implication and high incidence of bone and spinal metastases, the molecular mechanisms behind prostate cancer metastasis to bone and spine are not well understood. In this review, the molecular mechanisms that may contribute to the highly metastatic phenotype of prostate cancer are discussed. Proangiogenic factors such as vascular endothelial growth factor (VEGF) have been shown to not only aid in the metastatic capabilities of prostate cancer but also encourage the colonization and growth of prostate tumour cells in the skeleton. The importance of VEGF in the complex process of prostate cancer dissemination to the skeleton is discussed, including its role in the development of the bone premetastatic niche, metastatic tumour cell recognition of bone, and bone remodeling. The expression of VEGF has also been shown to be upregulated in prostate cancer and is associated with clinical stage, Gleason score, tumour stage, progression, metastasis, and survival. Due to the multifaceted effect VEGF has on tumour angiogenesis, tumour cell proliferation, and bone destruction, therapies targeting the VEGF pathways have shown promising clinical application and are being investigated in clinical trials.

1. Introduction

The five-year survival rate for prostate cancer is extremely high when confined to the prostate, but in the presence of metastatic disease it is reduced to 33% [1]. In Australia, prostate cancer contributes to almost 5% of all registered male deaths [2] of which more than 80% will have developed spinal metastases during the course of their disease [3–5]. Once cancer metastasizes to bone and the vertebral column, patients often experience intractable pain and neurological deficit due to pathological fractures, spinal instability, and metastatic epidural spinal cord compression. The neurological sequelae include sensory disturbance, motor weakness, paralysis, and incontinence, leading to decreased function, inability to ambulate and impaired quality of life [5]. Treatment options include radiotherapy, hormonal therapy, chemotherapeutic agents such as docetaxel, cabazitaxel, sipuleucel-T and abiraterone acetate, and decompression and stabilization surgery [6, 7]. These modalities may be able to extend survival rates but are all predominantly palliative, with median survival time limited from one to two years from the onset of metastases [5, 6]. Despite the clinical implication and high incidence of spinal metastasis, the molecular mechanisms behind prostate cancer metastasis to bone and the spine are not well understood. Vascular endothelial growth factor (VEGF) is well known to be potent stimulator of angiogenesis in both physiological and pathological conditions and is highly expressed in most solid tumours, including prostate cancer. This review discusses the role of VEGF in tumour angiogenesis and bone destruction in metastatic prostate cancer to the spine.

2. VEGF and Its Receptors

VEGF is a ligand of the VEGF tyrosine kinase receptor superfamily and includes VEGF-A, -B, -C and -D, with splice variants of VEGF-A resulting in several different isoforms [8, 9]. The VEGF family ligands bind to tyrosine kinase receptors VEGFR1, VEGFR2, and VEGFR3 (Figure 1), each receptor containing an extracellular domain of approximately 750 amino acid residues, arranged within seven
immunoglobulin-like folds [10]. Additionally, heparin sul-
phate proteoglycans (HSPGs) as well as neuropilins (NRP-1
and NRP-2) can act as coreceptors for VEGF and promote
VEGFR activation [11, 12]. Each VEGF family member binds
with differential affinity for their receptors; for example,
VEGFR2 is primarily activated by VEGF-A and VEGFR3 is
only activated by VEGF-C and -D. Upon specific VEGF bind-
ing, the three VEGF receptors induce receptor dimerization
and autophosphorylation leading to downstream signaling
via a number of secondary messengers including several
protein kinases and phosphatases that support a proangio-
genic phenotype [10–12]. Important pathways include the
phosphoinositide 3-kinase/Protein Kinase B/NF-κB pathway
that promotes cell survival, the mitogen-activated protein
kinase (MAPK) pathway that promotes cell proliferation, and
the Ras/extracellular signal-regulated kinase (ERK) pathway
that promotes cell proliferation, survival, differentiation,
migration, and angiogenesis. Through these signaling path-
ways each of the VEGF family provides different actions,
with VEGF-A activation of VEGFR2 representing the major
mediator of angiogenesis induction [13–15].

There are many factors that influence and regulate
the VEGF/VEGFR pathway, including local environmen-
tal hypoxia and various hormones, growth factors, and
cytokines. Hormones such as androgens upregulate stromal
cell and malignant cell VEGF production and angiogenesis,
enhancing prostate cancer growth [16–18]. As such, hormone
withdrawal has been shown to inhibit VEGF expression
as well as angiogenesis in prostate cancer patients while inducing apoptosis in these cells [19]. Growth factors such as PDGFs, TGF-β1, and IGFs also have a significant impact on the VEGF/VEGFR pathway by inducing the transcription and secretion of VEGF [18, 20, 21]. Cytokines such as TNF-α, IL-6, and IL-8 have also been shown to induce VEGF signalling to promote angiogenesis and tumourogenesis [22, 23], IL-6 and IL-8 are also involved with the PI3 K/Akt/NF-κB pathways as well as the MAPK pathway of VEGF signalling [24, 25].

3. VEGF and Angiogenesis

Angiogenesis is the growth and development of new blood vessels and is necessary to supply nutrients and maintain homeostasis in the tissues of the body [12]. Normal angiogenesis is tightly regulated by inducers and inhibitors of endothelial growth and is established from preexisting vessels, which develop ordered and predictable vasculature [26]. The actions of VEGF affect numerous cell types, thus enabling a multifaceted response. Initial activation of VEGF promotes the secretion of proteolytic enzymes to degrade the basement membrane and extracellular matrix whilst also aiding in the proliferation and migration of endothelial cells to form immature vasculature [13, 26]. VEGF also maintains newly formed vessels by inducing the expression of Bcl-2 and A1 anti-apoptotic proteins that promote cell survival, whilst activating colony formation by attracting mature subsets of granulocyte macrophage progenitor cells [27, 28]. VEGF-A exhibits vast up-regulation under hypoxic conditions whereby hypoxia-inducible factors (HIFs) stabilize and bind to specific promoter elements present in the promoter region of VEGF-A [11]. VEGFR1 and VEGFR2 are also directly regulated by HIFs [11].

In cancer, alterations in this balance of inducers and inhibitors in favour of angiogenesis can stimulate an "angiogenic switch", via overexpression of pro-angiogenic factors such as VEGF by tumour cells and tumour-associated stroma [26, 29]. Hypoxic conditions activate the uptake of VEGF and other growth factors and induce the growth of neovascularization, allowing the tumour cells to gain access to oxygen and nutrients [26, 29–31]. Indeed, the induction of angiogenesis has been shown to correlate with the invasive properties of tumours and is associated with poor prognosis [32]. Along with tumour vascularization, activation of genes governing the disruption of cell to cell adhesion and cell motility enables proliferation of primary tumour cells as well as allowing detached cells to disseminate throughout the circulatory system [28]. In benign prostate glands, VEGF expression is mainly confined to the basal cell layer and has weak levels of VEGF binding, while in prostate tumours VEGF is upregulated and found beyond this layer, including neoplastic secretory cells [33].

4. VEGF and Skeletal Metastasis

During the normal development of long bones and vertebrae or bone repair, growth and remodeling of bone formation occurs through osteogenesis [34]. A balanced state is created through the continuous and integrated processes of bone formation and deposition by osteoblasts and bone and mineralized matrix resorption by proteolytic enzymes and hydrochloric acid secreted by osteoclasts, derived from the haematopoietic stem cells of the bone marrow [35, 36]. It is a complex process dictated by growth factors and cytokines including fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), and bone morphogenetic proteins (BMPs) [34]. VEGF is expressed by osteoblasts and has autocrine and paracrine effects including chemotactic migration, proliferation, and differentiation of osteoblasts, as well as stimulating the formation, survival, and resorptive activity of osteoclasts. It is essential for normal angiogenesis and appropriate bone repair and mineralization in response to bone injury [37]. In vivo, absence of VEGF leads to impaired blood vessel invasion, cartilage remodeling, and skeletal growth [38–40]. Blood vessels serve as a way of transporting circulating osteoblasts [41] and osteoclast precursors [42] to sites undergoing active remodelling [43]. Cancer metastases to bone cause alterations in normal bone metabolism and the balance between osteoclasts and osteoblasts in favour of one or the other, resulting in destructive lytic or sclerotic lesions, or a combination of both [44]. Osteoclasts are primarily responsible for tumour induced bone destruction, and during the resorption of the bone matrix, embedded growth factors are released that produce a permissive microenvironment and further promote tumour growth [30, 45]. Of note, in human prostate cancer, bone metastases generally favour an osteoblastic phenotype, in contrast to other metastases such as those from renal cell carcinoma, which are often lytic [46, 47].

The spread of prostate cancer metastasis to bone is a complex process involving tumour cell migration from the primary tumour site, dissemination through the vascular system, extravasation, and finally establishment, growth, and invasion at the secondary bone site [4]. In a clinical trial of patients with metastatic prostate cancer, bone metastases were noted in 88.9% of patients, compared with soft tissue/lymph node metastases in 22.2% and visceral metastases in 16.7%, demonstrating the preferential homing capabilities of prostate metastasis to bone [48]; however the propensity of prostate cancer to metastasize to bone and the vertebral column remains largely unknown. Prior to the attachment of these cancer cells to bone, it is thought that a premetastatic niche may be created by nonmalignant bone marrow-derived cells that are stimulated by tumour-secreted proteins, which in combination with various bone-enriched growth factors, cytokines, proteases, and components of the extracellular matrix such as a high extracellular calcium concentration support the colonization and growth of prostate cancer cells in bone [49–51]. The actions of VEGF are thought to assist in tumour cell recognition of bone and encourage nesting of the tumour cells in bone [52]. Prior to attachment, VEGF via VEGFR2 modulates the migratory responses of tumour cells encouraging adhesion molecules such as fibronectin and bone sialoprotein within the extracellular matrix [53]. Additionally, VEGF and its cognate receptors may be able to regulate integrin activity, promoting recognition of the
bone matrix [32]. Various tumour-expressed growth factors, endothelial markers, and cytokines attract and activate osteoclasts, which in turn disrupt the bone balance through overstimulation and discharge of bone-derived growth factors (Figure 2). Other factors which affect the progression of prostate cancer to bone are Dickkopf-1 (DKK-1), sclerostin, and Wnt signalling. Uptregulation of DKK-1 and sclerostin enhances osteoclastic activity by suppressing Wnt signalling and is thought to be able to inhibit the advancement of bone cancer metastases [54, 55]. Whilst DKK-1 levels in patients with bone metastases decrease, Wnt levels rise [56]. This increase of Wnt signalling promotes osteoblast and inhibits osteoclast differentiation, leading to an osteoblastic tumour phenotype [56, 57]. Furthermore, in response to various hormonal, cellular, and cytokine signals, receptor activator of nuclear factor κ B ligand (RANKL), induces osteoclast formation and activation [58, 59]. Osteoprotegerin (OPG) may act as a decoy receptor for RANKL in order to inhibit osteoclastogenesis, which in turn increases osteoblast formation [60]. This RANK/RANKL/OPG axis therefore is important in determining the phenotype of the bone tumour [59]. These factors are deposited into the bone matrix and create a microenvironment that is favourable for cancer cells, leading to further proliferation of tumour cells and bone degradation through the secretion of osteolytic factors [61].

Expression levels of VEGF and VEGFRs have also been shown to be elevated at the site of bone metastases in comparison to primary prostate tumours, indicating that VEGF is an important factor in metastasis development, particularly to bone [53]. Increased VEGF plasma levels have been shown to correlate with skeletal metastasis and poor prognosis in prostate cancer patients and VEGF expression levels in many cancer types have been shown to correlate with poorer prognosis and metastatic potential [62]. However, other studies have shown that there is no correlation between VEGF serum levels and prognosis [63, 64]. The expression of VEGF is upregulated in prostate cancer and is associated with clinical stage, Gleason score, tumour stage, progression, metastasis and survival [65–67]. In prostate cancer VEGF-dependent autocrine stimulation activates the αVβ3 integrin via the VEGFR2 receptor leading to cell proliferation, survival and recognition of extracellular matrix components, which may influence their metastatic capabilities [53]. Many prostate cancer cell lines known to produce osteoblastic metastases highly express VEGF [68].

Interactions of VEGF with markers such as TNF-α, IL-6, IL-8, and CCN3 have been linked to the pro-angiogenic activities of tumour cells [69–71]. High expression of VEGF has been observed in human metastatic prostate cancer cell lines PC-3, Du145, and line LNCaP-C4–2, where it has been shown to promote osteoblastic differentiation and activity in vitro [53, 71–73].

5. Current Treatment of Prostate Cancer and VEGF/VEGF-R Targeted Therapies

Traditionally, androgen ablation has been the main treatment for the prevention of metastases from prostate cancer. As prostate cancer cells are initially dependant on androgens, suppressing the levels of testosterone and dihydrotestosterone decreases the growth rate of prostate cancer cells [74]. However, after this initial response these cells can become castrate-resistant and develop a more aggressive phenotype, with increased VEGF expression and proliferative potential [74, 75]. The most common conventional treatments for bone metastases secondary to prostate cancer are chemotherapy, radiation, and surgery. Although chemo- and radiotherapy has the potential ability to kill rapidly dividing cancer cells, they each have their own toxic side effects and there is little survival benefit in patients with metastatic cancer [76, 77]. Bisphosphonates such as zoledronic acid or Denosumab, a human monoclonal antibody that targets RANKL signalling, also have a therapeutic role in preventing skeletal-related events in bone metastases via inhibition of osteoclast-mediated bone resorption [78]. Patient morbidity and mortality due to local tumour recurrence, multimetastatic disease, loss of structural function of the bony skeleton destroyed by tumour, and metastatic epidural nerve or spinal cord compression remain important challenges.

Due to the multifaceted effect VEGF has on tumour angiogenesis, tumour cell proliferation, and bone destruction, antiangiogenic therapies targeting the VEGF pathways have shown promising early clinical application and are being investigated in clinical trials. These anti-VEGF therapies consist of VEGF-neutralizing antibodies and tyrosine kinase receptor inhibitors. Bevacizumab is a monoclonal IgG1 antibody that blocks the binding of VEGF-A to its receptors by neutralizing all VEGF isoforms and bioactive proteolytic fragments through the binding of the antibody Fab-ligand epitope to the Gly88 residue of VEGF [79]. Bevacizumab is currently in Phase II clinical trials in relapsed prostate cancer and is approved by the US Food and Drug Administration (FDA) for treatment of metastatic colorectal, renal, and breast cancer and other solid tumours [80, 81]. Similarly, Aflibercept is another antibody which neutralizes VEGF and is currently being used in Phase II clinical trials for patients with recurrent or metastatic urothelial cancer [82]. Tyrosine kinase inhibitors act on VEGF receptors inhibiting activation following ligand binding [83]. Ramucirumab is a human IgG1 monoclonal antibody which binds to the extracellular domain of VEGFR-2 and blocks the VEGF-A to VEGFR-2 interaction and subsequent downstream signaling [84]. Other small molecule tyrosine kinase receptor inhibitors include Semaxanib, which targets a single receptor (VEGFR2), and Sorafenib, which targets multiple tyrosine kinase receptors VEGFR1, -2 and -3, as well as platelet-derived growth factor receptor-β [83, 85]. Recently, studies have suggested that using anti-VEGF therapies such as Bevacizumab in concert with radiation therapy or chemotherapy may be able to increase the response to radiation therapy [86]. These synergistic actions have been reported in several preclinical studies and have been shown to improve the survival rates in patients with advanced cancers and decrease levels of radiation necrosis [86–88].

Prostate Cancer
6. Conclusion

To date there have been many articles published suggesting the possible molecular mechanisms behind the propensity of prostate cancer to metastasize to bone and the vertebral column. VEGF has been implicated in many of these, including facilitating cancer cell migration to bone, induction of angiogenesis, and stimulating bone forming and resorbing cells of the bone marrow. Anti-angiogenic treatments targeting the VEGF/VEGF receptor pathway have shown promising early clinical application. Further research is required to determine whether this may be translated into better disease control, decreased morbidity, higher survival rates, and improved quality of life in patients with prostate cancer.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

This work was supported by the National Health and Medical Research Council of Australia (Fellowship no. 558418), the Austin Health Medical Research Foundation, and the Victorian Orthopaedic Research Trust.

References

[1] "Statistics, A.B.o., 3303. 0 Causes of Death, Australia," 2012. http://www.abs.gov.au/ausstats/abs@.nsf/Products/E0BA9CC2096 C3886CA25788400127C4C?opendocument.
[2] S. C. Gupta, J. H. Kim, S. Prasad, and B. B. Aggarwal, "Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals," Cancer and Metastasis Reviews, vol. 29, no. 3, pp. 405–434, 2010.
[3] K. Pietras and A. Østman, "Hallmarks of cancer: interactions with the tumor stroma," Experimental Cell Research, vol. 316, no. 8, pp. 1324–1331, 2010.
[4] I. Roato, P. D'Amelio, E. Gorassini et al., “Osteoclasts are active in bone forming metastases of prostate cancer patients,” *PloS ONE*, vol. 3, no. 11, Article ID e3627, 2008.

[5] S. A. Meyer, H. Singh, and A. L. Jenkins, “Surgical treatment of metastatic spinal tumors,” *Mount Sinai Journal of Medicine*, vol. 77, no. 1, pp. 124–129, 2010.

[6] E. J. Brown and E. Chow, “Bone biomarkers in research and clinical practice,” in *Bone Metastases*, vol. 12 of *Cancer Metastasis—Biology and Treatment*, pp. 93–116, 2009.

[7] M. E. McGee-Lawrence and J. J. Westendorf, “Histone deacetylases in skeletal development and bone mass maintenance,” *Gene*, vol. 474, no. 1-2, pp. 1–11, 2011.

[8] R. L. Clifford, K. Deacon, and A. J. Knox, “Novel regulation of vascular endothelial growth factor A (VEGFA) by transforming growth factor β1: requirement for Smads, β-catenin, and GSK3β,” *Journal of Biological Chemistry*, vol. 283, no. 51, pp. 35337–35353, 2008.

[9] F. Fan, J. S. Wey, M. F. McCarty et al., “Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells,” *Oncogene*, vol. 24, no. 16, pp. 2647–2653, 2005.

[10] A. K. Olsson, A. Dimberg, J. Kreuger et al., “VEGF receptor signalling—in control of vascular function,” *Nature Reviews Molecular Cell Biology*, vol. 7, no. 5, pp. 359–371, 2006.

[11] N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” *Nature Medicine*, vol. 9, no. 6, pp. 669–676, 2003.

[12] H. Takahashi and M. Shibuya, “The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions,” *Clinical Science*, vol. 109, no. 3, pp. 227–241, 2005.

[13] T. L. Phung, K. Ziv, D. Dabydeen et al., “Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin,” *Cancer Cell*, vol. 10, no. 2, pp. 159–170, 2006.

[14] J. D. Hood, R. Frausto, W. B. Kiosses, M. A. Schwartz, and D. A. Cheres, “Differential α/γ integrin-mediated Ras-ERK signaling during two pathways of angiogenesis,” *Journal of Cell Biology*, vol. 162, no. 5, pp. 933–943, 2003.

[15] X. Jin, J. Yin, S.-H. Kim et al., “EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction,” *Cancer Research*, vol. 71, no. 22, pp. 7125–7134, 2011.

[16] A. C. Levine, X.-H. Liu, P. D. Greenberg et al., “Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts,” *Endocrinology*, vol. 139, no. 11, pp. 4672–4678, 1998.

[17] M. W. Jackson, “A potential autocrine role for vascular endothelial growth factor in prostate cancer,” *Cancer Research*, vol. 62, pp. 854–859, 2002.

[18] X. Li, Y. Feng, J. Liu et al., “Epigallocatechin-3-gallate inhibits IGF-1-stimulated lung cancer angiogenesis through down-regulation of HIF-1α and VEGF expression,” *Journal of Nutriogenetics and Nutrionomics*, vol. 6, no. 3, pp. 169–178, 2013.

[19] R. K. Jain, N. Safabakhsh, A. Skell et al., “Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 18, pp. 10820–10825, 1998.

[20] J. Yu, C. Ustach, and H.-R. C. Kim, “Platelet-derived growth factor signaling and human cancer,” *Journal of Biochemistry and Molecular Biology*, vol. 36, no. 1, pp. 49–59, 2003.

[21] K. Eisemann, C. J. Broderick, A. Bazavov et al., “Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site,” *Molecular Cancer*, vol. 12, p. 7, 2013.

[22] T. Cohen, D. Nahari, L. W. Cerem, G. Neufeld, and B.-Z. Levin, “Interleukin 6 induces the expression of vascular endothelial growth factor,” *Journal of Biological Chemistry*, vol. 271, no. 2, pp. 736–741, 1996.

[23] Z. Von Marschall, T. Cramer, M. Höcker, G. Finkenzeller, B. Wiedenmann, and S. Rosewicz, “Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma,” *Gut*, vol. 48, no. 1, pp. 87–96, 2001.

[24] B. Paule, S. Terry, L. Kheuang, P. Soyeux, F. Vacherot, and A. de Taille, “The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?” *World Journal of Urology*, vol. 25, no. 5, pp. 477–489, 2007.

[25] F. Luppi, A. M. Longo, W. I. de Boer, K. F. Rabe, and P. S. Hiemstra, “Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation,” *Lung Cancer*, vol. 56, no. 1, pp. 25–33, 2007.

[26] B. I. Terman and K. V. Stoletov, “VEGF and tumor angiogenesis,” *The Einstein Quarterly Journal of Biology and Medicine*, vol. 18, no. 2, 2001.

[27] S. P. Ivy, J. Y. Wick, and B. M. Kaufman, “An overview of small-molecule inhibitors of VEGF signaling,” *Nature Reviews Clinical Oncology*, vol. 6, no. 10, pp. 569–579, 2009.

[28] P. G. Tsoutsou and M. I. Koukourakis, “Angiogenesis and bone metastasis: implications for diagnosis, prevention and treatment,” in *Bone Metastases*, vol. 12 of *Cancer Metastasis—Biology and Treatment*, pp. 51–76, 2009.

[29] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” *Cell*, vol. 144, no. 5, pp. 646–674, 2011.

[30] G. Van Der Pluijm, B. Sijmons, H. Vloedgraven, M. Deckers, S. Papapoulos, and C. Löwik, “Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases,” *Journal of Bone and Mineral Research*, vol. 16, no. 6, pp. 1077–1091, 2001.

[31] R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell metabolism,” *Nature Reviews Cancer*, vol. 11, no. 2, pp. 85–95, 2011.

[32] S. De, J. Chen, N. V. Narizhneva et al., “Molecular pathway for cancer metastasis to bone,” *Journal of Biological Chemistry*, vol. 278, no. 40, pp. 39044–39050, 2003.

[33] J. Köllermann and B. Helpap, “Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue,” *American Journal of Clinical Pathology*, vol. 116, no. 1, pp. 115–121, 2001.

[34] V. J. Mandracchia, S. C. Nelson, and E. A. Barp, “Current concepts of bone healing,” *Clinics in Podiatric Medicine and Surgery*, vol. 18, no. 1, pp. 55–77, 2001.

[35] B. F. Boyce, E. Rosenberg, A. E. de Papp et al., “The osteoclast, bone remodelling and treatment of metabolic bone disease,” *European Journal of Clinical Investigation*, vol. 42, no. 12, pp. 1332–1341, 2012.

[36] J. Street and B. Lenehan, “Vascular endothelial growth factor regulates osteoblast survival—evidence for an autocrine feedback mechanism,” *Journal of Orthopaedic Surgery and Research*, vol. 4, no. 1, article 19, 2009.

[37] R. A. D. Carano and E. H. Filvaroff, “Angiogenesis and bone repair,” *Drug Discovery Today*, vol. 8, no. 21, pp. 980–989, 2003.
J.-K. Jin, F. Dayyani, and G. E. Gallick, "Steps in prostate cancer," *BoneKEy Reports*, vol. 1, p. 101, 2012.

S. M. Tu, A. Som, B. Tu et al., "Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis," *British Journal of Cancer*, vol. 107, no. 4, pp. 646–651, 2012.

Y. Li, D. Kong, A. Ahmad, B. Bao, and F. H. Sarkar, "Targeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasis," *PLoS ONE*, vol. 7, no. 3, Article ID e30011, 2012.

D. L. Lacey, W. J. Boyle, W. S. Simonet et al., "Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab," *Nature Reviews Drug Discovery*, vol. 11, no. 5, pp. 401–419, 2012.

L. Mercatali, M. Ricci, E. Scarpi et al., "RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study," *International Journal of Molecular Sciences*, vol. 14, no. 6, pp. 10683–10693, 2013.

T. A. Guise, K. S. Mohammad, G. Clines et al., "Basic mechanisms responsible for osteolytic and osteoblastic bone metastases," *Clinical Cancer Research*, vol. 12, no. 20, pp. 6213s–6216s, 2006.

J. L. F. Duque, K. R. Loughlin, R. M. Adam, P. W. Kantoff, D. Zurakowski, and M. R. Freeman, "Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer," *Urology*, vol. 54, no. 3, pp. 523–527, 1999.

P. J. Saylor, K. R. Kozak, M. R. Smith et al., "Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer," *Oncologist*, vol. 17, no. 2, pp. 212–219, 2012.

F. Botelho, F. Pina, P. Silva, G. Figueiredo, D. Cruz, and N. Lunet, "Vascular endothelial growth factor (VEGF) and prostate pathology," *International Brazilian Journal of Urology*, vol. 36, no. 4, pp. 430–438, 2010.

E. K. Amankwah, T. A. Sellers, and J. Y. Park, "Gene variants in the angiogenesis pathway and prostate cancer," *Carcinogenesis*, vol. 33, no. 7, pp. 1259–1269, 2012.

M. Borre, S. M. Bentzen, B. Nørstrøm, and J. Overgaard, "Tumor cell proliferation and survival in patients with prostate cancer followed expectantly," *Journal of Urology*, vol. 159, no. 5, pp. 1609–1614, 1998.

T. T. Tomiá, H. Gustavsson, W. Wang, K. Jennisbacken, K. Welén, and J.-E. Damber, "Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2," *Prostate*, vol. 72, no. 7, pp. 705–712, 2012.

N. K. Thudi, C. K. Martin, M. V. P. Nadella et al., "Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions," *Prostate*, vol. 68, no. 10, pp. 1116–1125, 2008.

G. Ligresti, A. C. Aplin, P. Zorzi, A. Morishita, and R. F. Nicossia, "Macrophage-derived tumor necrosis factor-α is an early component of the molecular cascade leading to angiogenesis in response to aortic injury," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 31, no. 5, pp. 1151–1159, 2011.

C. Fischbach, J. K. Hyun, S. X. Hsing, M. B. Evangelista, W. Yuen, and D. J. Mooney, "Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 2, pp. 399–404, 2009.
[71] V. Ouellet and P. M. Siegel, "CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis," *Journal of Cell Communication and Signaling*, vol. 6, no. 2, pp. 73–85, 2012.

[72] Y. Takei, K. Kadomatsu, Y. Yuzawa, S. Matsuo, and T. Muramatsu, "A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics," *Cancer Research*, vol. 64, no. 10, pp. 3365–3370, 2004.

[73] S. Srinivasan, R. Kumar, S. Koduru, A. Chandramouli, and C. Damodaran, "Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer," *Apoptosis*, vol. 15, no. 2, pp. 153–161, 2010.

[74] E. Corey, "Androgen suppression: the good, the bad and the ugly," *Andrology*, vol. 1, Article ID e106, 2012.

[75] L. Pan, S. Baek, P. R. Edmonds et al., "Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610," *Radiation Oncology*, vol. 8, article 100, 2013.

[76] L. Yang, S. You, V. Kumar et al., "In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line," *Journal of Experimental & Clinical Cancer Research*, vol. 31, article 40, 2012.

[77] T. Brabietz, D. Lyden, P. S. Steeg et al., "Roadblocks to translational advances on metastasis research," *Nature Medicine*, vol. 19, no. 9, pp. 1104–1109, 2013.

[78] N. Kamiya, H. Suzuki, T. Endo et al., "Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade," *International Journal of Urology*, vol. 19, no. 2, pp. 169–173, 2012.

[79] A. F. Dawood, P. Lotfi, S. N. Dash, S. K. Kona, K. T. Nguyen, and M. I. Romero-Ortega, "VEGF release in multiluminal hydrogels directs angiogenesis from adult vasculature in vitro," *Cardiovascular Engineering and Technology*, vol. 2, no. 3, pp. 173–185, 2011.

[80] V. T. Labropoulou, A. D. Theocharis, A. Symeonidis, S. S. Skandalis, N. K. Karamanos, and H. P. Kalofonos, "Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions," *Current Medicinal Chemistry*, vol. 18, no. II, pp. 1584–1598, 2011.

[81] K. N. Syrigos, E. Karapanagiotou, P. Boura, C. Manegold, and K. Harrington, "Bevacizumab-induced hypertension: pathogenesis and management," *BioDrugs*, vol. 25, no. 3, pp. 159–169, 2011.

[82] P. Twtradowski, W. M. Stadler, P. Frankel et al., "Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer: a California cancer consortium trial," *Urology*, vol. 76, pp. 923–926, 2010.

[83] S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling," *Molecular Cancer Therapeutics*, vol. 7, no. 10, pp. 3129–3140, 2008.

[84] A. Grothey and E. Galanis, "Targeting angiogenesis: progress with anti-VEGF treatment with large molecules," *Nature Reviews Clinical Oncology*, vol. 6, no. 9, pp. 507–518, 2009.

[85] A. O’Donnell, A. Padhani, C. Hayes et al., "A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points," *British Journal of Cancer*, vol. 93, no. 8, pp. 876–883, 2005.

[86] A. Narayana, D. Gruber, S. Kunnakkat et al., "A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma: clinical article," *Journal of Neurosurgery*, vol. 116, no. 2, pp. 341–345, 2012.

[87] H. I. Hurwitz, N. C. Tebbutt, F. Kabbinavar et al., "Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials," *Oncologist*, vol. 18, no. 9, pp. 1004–1012, 2013.

[88] M. Furuse, N. Nonoguchi, S. Kawabata et al., "Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET," *Japanese Journal of Clinical Oncology*, vol. 43, no. 3, pp. 337–341, 2013.